肌肉减少对卵巢癌患者生存无影响:前瞻性验证研究
本研究基于随机III期OVHIPEC试验中III期卵巢癌接受新辅助化疗(NACT)的患者,于基线和两周期化疗后行CT扫描计算骨骼肌指数(SMI),分析ΔSMI与预后的关系。212/245例(87%)有配对CT,ΔSMI下降组与稳定/升高组的中位无复发生存和总生存均无显著差异(p=0.297和p=0.764),但SMI下降与更多术前不良事件及3-4级不良事件相关。
要点
- ΔSMI下降与III期卵巢癌NACT患者RFS和OS无显著相关
- SMI下降组术前不良事件及3-4级不良事件更多
- 不推荐将NACT期间SMI下降作为预后分层依据
核心结论
- 在新辅助化疗期间骨骼肌指数下降与OVHIPEC试验中III期卵巢癌患者的预后不良无关。
- 骨骼肌指数下降与不良事件之间存在强关联。
研究设计与样本
- 基于随机III期OVHIPEC试验的前瞻性验证研究,纳入III期卵巢癌接受新辅助化疗的患者。
- 在基线和两个周期新辅助化疗后行CT扫描,共212/245例(87%)患者有配对CT扫描。
- 使用SliceOMatic软件计算骨骼肌指数(SMI),并计算两次CT间SMI差值(ΔSMI)。
- 采用Cox回归分析ΔSMI对结局的独立效应,Log-rank检验绘制无复发生存(RFS)和总生存(OS)曲线。
- 采用t检验比较组间每例患者平均不良事件数。
主要发现
- 两组中位RFS和OS均无显著差异(p=0.297和p=0.764)。
- SMI下降组患者经历更多术前不良事件,且3-4级不良事件更多。
临床怎么用
- 对III期卵巢癌接受新辅助化疗的患者,不宜依据SMI下降判断预后。
- SMI下降提示不良事件风险增加,可关注术前及治疗期间不良事件监测。
局限性
- 245例中仅212例(87%)有配对CT扫描,存在缺失数据。
- 研究为OVHIPEC试验的二次分析,结论需在其他人群验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Decrease in skeletal muscle index (SMI) during neoadjuvant chemotherapy (NACT) has been associated with worse outcome in patients with advanced ovarian cancer. To validate these findings, we tested if a decrease in SMI was a prognostic factor for a homogenous cohort of patients who received NACT in the randomized phase 3 OVHIPEC-trial. METHODS: CT-scans were performed at baseline and after two cycles of neoadjuvant chemotherapy in stage III ovarian cancer patients. The SMI (skeletal muscle area in cm2 divided by body surface area in m2) was calculated using SliceOMatic software. The difference in SMI between both CT-scans (ΔSMI) was calculated. Cox-regression analyses were performed to analyze the independent effect of a difference in SMI (ΔSMI) on outcome. Log-rank tests were performed to plot recurrence-free (RFS) and overall survival (OS). The mean number of adverse events per patient were compared between groups using t-tests. RESULTS: Paired CT-scans were available for 212 out of 245 patients (87%). Thirty-four of 74 patients (58%) in the group with a decrease in ΔSMI and 73 of 138 of the patients (53%) in the group with stable/increase in ΔSMI had died. Median RFS and OS did not differ significantly (p = 0.297 and p = 0.764) between groups. Patients with a decrease in SMI experienced more pre-operative adverse events, and more grade 3-4 adverse events. CONCLUSION: Decreased SMI during neoadjuvant chemotherapy was not associated with worse outcome in patients with stage III ovarian cancer included in the OVHIPEC-trial. However, a strong association between decreasing SMI and adverse events was found.
引用
- Ubachs J, Koole SN, Lahaye M, et al. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. Gynecol Oncol. 2020. PMID: 33019981. doi:10.1016/j.ygyno.2020.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。